Loading…
SLGL
Sol-Gel Technologies Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M8694L137
$68.81-5.18%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $225.28M
- P/E
- —
- Forward P/E
- —
- P/B
- 4.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$5.33
- ROE
- -40.85%
- Profit margin
- 0.00%
- Revenue growth
- -96.60%
- Beta
- 1.16
- 52-week high
- $97.97
- 52-week low
- $22.04
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -25.7% over 5Y.
today you would have $668.50▼ -33.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $42.14 | $9.30 | $11.05 | $45.60 | $74.00 | $97.90 | $171.50 | $60.20 | |
| P/E | — | — | — | — | — | 52.9x | — | — | 3.3x |
| P/S | 17.5x | 6.1x | 2.2x | 19.8x | 27.2x | 5.5x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALECAlector, Inc. | $2.02 | — | — | — | -385.11% | $225.55M |
| AMWLAmerican Well Corp | $13.21 | — | 1.0x | — | -29.12% | $224.69M |
| STIMNeuronetics, Inc. | $2.94 | — | 12.6x | — | -116.10% | $224.02M |
| CRDLCardiol Therapeutics Inc. | $1.94 |
About the company
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
- 28
- Ness Ziona, Israel
Company description provided by Yahoo Finance.